Abstract 3268
Background
Today we have much strong evidence that supports the early integration of palliative care into standard cancer care of all the patients with incurable cancer. At our Institution we have stablished an Acute Palliative Care Department (APCD) in 2007 and today we can provide a specialist palliative care as inpatient, outpatient and consultation service. Aim: to analyse the time frame of the referrals to palliative care services at our institution.
Methods
We collected data on the entire patient population who were supported with specialist palliative care at our instuitions between 2007–2015. We have also compared triads - periods between 2007-2009, 2010-2012 and 2013-2015.
Results
In the observed period 1842 palliative care patients (942 males, 913 females) have been served by at least one of the APCD services. At the time of the analyse 98% had already died. 99.9% of them had incurable cancer. 60% of them were treated at APCD inpatient unit, 23.5% at outpatient clinic and 15.9% were advised by specialist palliative care consultation team. The mean time of palliative care service referrals for the whole group and period was 54 days. When we compared the three triads between each other we observed a small trend to earlier referrals (2007-2009: 42days, 2010-2012: 51 days and 2013-2015: 61 days).
Conclusions
We observed earlier palliative care referrals in the last triad of the APCD existence at our institutions comparing first and second triad; still the referrals are late in the illness trajectory.
Clinical trial identification
Legal entity responsible for the study
Oncology Institute of Ljubljana
Funding
Oncology Institute of Ljubljana
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract